uploads/2018/02/GMED-analysts-reco-1.png

Analyst Ratings for Globus Medical and Its Peers in February

By

Updated

Company overview

Globus Medical (GMED) is a medical device company with a focus on designing, developing, and commercializing musculoskeletal solutions. It’s focused mainly on implants for patients with spine disorders and patients who have experienced orthopedic trauma.

Globus Medical’s sales force is comprised of direct sales representatives and distributor sales representatives employed by exclusive independent distributors. The company has a global presence and markets and sells products in the United States, North America, Central America, South America, Europe, Asia, Africa, and Australia.

Article continues below advertisement

Analyst ratings

Of the 13 analysts covering Globus Medical in February 2018, seven of them have given the stock a “buy” or higher rating. Five analysts have given it a “hold,” and one has given it a “sell.” The mean rating for the stock is 2.23 with a target price of $45.33.

Globus Medical makes up 0.18% of the iShares Core S&P Mid-Cap ETF’s (IJH) total portfolio holdings.

Peer ratings

Of the eight analysts covering AtriCure (ATRC) in February 2018, seven of them have given the stock a “buy” or higher rating, and one has given it a “hold.” The mean rating for the stock is 1.75 with a target price of $24.43.

Of the six analysts covering Inogen (INGN) in February 2018, four of them have given the stock a “buy” or higher rating, and two have given it a “hold.” The mean rating for the stock is 1.83 with a target price of $117.

Of the four analysts covering MiMedx Group (MDXG) in February 2018, one has given the stock a “strong buy” rating, and three have given it a “buy.” The mean rating for the stock is 1.75 with a target price of $19.

In the next part of this series, we’ll take a look at Globus Medical’s recent acquisitions.

Advertisement

More From Market Realist